Aqueous Pharma Ltd.

Innovative therapy for dry eye. 3 core tears developed by Dr. Frank Holly and optimal tear, Freshkote (APL-105), with 3 layers of the human tear. FDA compliant/CE Mark approved. ONLY non-irritating & non-allergenic ophthalmic preservative licensed to Big Pharma. BREAKING NEWS: APL-106 with only chemical well proven to stimulate tear production. Patents pending globally.

Activity:

- Licensing & Business Development
- Research & Development

Product / Technology type(s) covered:

- Curative
- Devices
- NCE (new chemical entities)
- OTC (over the counter drugs)
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)
- Technology

Therapeutic targets:

- Arthritis / Rheumato
- Ophthalmology
- Women's Health

Markets Covered

a. HeadQuarter: Portugal

b. Continent(s) active: Europe , North America , Far East , Asia , Central/South America , Near/Middle East , Australia/New-Zealand , Africa

c. Countries active: Europe, No. America, Japan, Korea, China, India, South America

Corporate data:

Number of Employees: 5

Turnover:

Amount:	Year:	Currency:
-	2006	Euro

Year founded: 2001

Partners / Alliances: The Dry Eye Institute -
www.dry-eye-institute.org
FOCUS Labs, Inc -
www.freshkote.com -
Farmigea SpA - www.farmigea.it - Dry Eye Co. - www.dryeyecompany.com - Altacor Ltd - www.altacor-pharma.com